関連する実験動画
Updated: Jun 1, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
BCL6は,Ph+の急性リンパ性白血病細胞がBCR-ABL1キナーゼ阻害を生き延びることを可能にします
Cihangir Duy1, Christian Hurtz, Seyedmehdi Shojaee
1Department of Laboratory Medicine, University of California San Francisco, San Francisco, California 94143, USA.
Nature
|May 20, 2011
まとめ
タイロシンキナーゼ阻害剤 (TKI) は,白血病を誘発する細胞を排除できず,再発につながる可能性があります. BCL6をターゲットにすることで,保護フィードバックシグナリングを阻害し,耐性白血病サブクローンを根絶することによって,この薬剤耐性を克服します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 血液学 ヘマトロジ
背景:
- タイロシンキナーゼ阻害剤 (TKI) は,BCR-ABL1-陽性白血病の標準治療法である.
- 現在のTKIは,しばしば白血病発症細胞 (LIC) を根絶できず,疾患の再発を引き起こす.
研究 の 目的:
- 白血病におけるTKI抵抗性の新しいメカニズムを調査する.
- 薬剤耐性を克服し,LICを根絶するための治療目標の特定.
主な方法:
- 薬剤耐性白血病細胞の信号伝達経路の分析.
- TKI抵抗における主要な規制者の特定.
- 臨床前モデルにおいて,特定された耐性経路の標的的抑制.
主要な成果:
- 白血病細胞における保護的フィードバックシグナル伝達を含む新しい薬剤耐性メカニズムを発見した.
- BCL6を,この抵抗経路の中心的媒介体として特定した.
- BCL6の阻害が薬剤耐性および白血病発症サブクローンを根絶することを実証した.
結論:
- BCL6を標的にすることは,白血病におけるTKI耐性を克服するための有望な戦略です.
- BCL6の抑制は,持続的な白血病の発症細胞を排除し,再発を防ぐことができます.
関連する概念動画
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...